Bayer-expects-dynamic-growth-higher-profitability-coming-years-accelerating-transformation

Crop Science: Clear innovation leader in its industry – expected sales and earnings growth above market / Pharmaceuticals: Further growth planned through 2023, new products expected to largely offset the effect of patent expirations – position in cell and gene therapy to be expanded / Consumer Health: Moved from industry underperformer to outperformer – further sales and earnings improvements planned / Core earnings per share anticipated to increase to 7.00 to 7.50 euros by 2024 / Further operational improvements to raise free cash flow to 5 billion euros by 2024 / Bayer in an excellent position to benefit from the biorevolution in health and nutrition
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news